New US patent for SBECD purification by CycloLab
The status of US patent application 17/344,217 (“Purification of sulfobutylated cyclodextrins with specific ion exchange resins” by CycloLab, Hungary) was
Tag: SBECD
Case Report: Severe SARS-CoV-2 Infection Treated with Remdesivir in a Patient with ESRD
Remdesivir has emerged as a promising antiviral drug against SARS-CoV-2. However, data regarding the clinical benefits of remdesivir in patients
SBECD in food and food packaging
A multifunctional food packaging material (G-Eug-NPs-NF) based on gelatin nanofiber membranes (G-NF) containing eugenol nanoparticles (Eug-NPs) were prepared [1]. The
Oil-free eye drops containing Cyclosporine A/SBECD/PVA supramolecular complex
According to the global mapping of dry eye disease (DED), nearly 5 to 50 % of people suffer from DED,
SBECD polymer to prolong the antibacterial activity
SBECD polymer was prepared by crosslinking with 1,6-hexamethylene diisocyanate. Iin vitro studies were conducted on two Escherichia coli strains that differed in
An Updated Overview of Cyclodextrin-Based Drug Delivery Systems for Cancer Therapy
Cyclodextrins (CDs) attracted increasing interest over the past few years, leading to the emergence of promising anti-tumor nanomedicines. Tackling their
Molecular docking assisted exploration on solubilization of poorly soluble drug remdesivir in sulfobutyl ether-beta-cyclodextrin: stabilization of supersaturated solution by changing pH from 1.7 to 3.5
In terms of solubilization effect, it was found that phase solubility of RDV increased significantly from intrinsic 1.7 mmol/L at
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
There were 648 patients enrolled in the study (216 cases and 432 controls). Viral clearance (VC) was observed in 490
Pharmacokinetic study of sulfobutylether beta-cyclodextrin as an excipient of remdesivir
SBECD (Captisol®) with an average degree of substitution of 6.5 sulfobutylether functional groups (SBE = 6.5), is a solubility enhancer
Inaugural Lecture of Prof. Szente at the Hungarian Academy of Sciences
Lajos Szente, Ph.D., D.Sc., one of the founders and former CEO (now Scientific Advisor) of CycloLab at the company and